GH1 and pituitary gland adenoma: Compared to patients with a nonfunctioning pituitary adenoma, no statistically significant difference in the incidence hazard ratio (Table 2) exists for CP patients receiving growth hormone treatment, according to the analysis by Verweij et al. [28].